This site is intended for healthcare professionals only

Diabetes &
Primary Care

Issue:

Share this article

+ Add to reading list - Remove from my list

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Stephen Bain

An unexpected safety signal emerged from the SUSTAIN 6 cardiovascular outcomes trial of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, whereby increased rates of diabetic retinopathy were observed in trial participants randomised to semaglutide. This finding has, justifiably, led to a great deal of investigation and caution. This At a Glance factsheet outlines the evidence regarding diabetic retinopathy in users of the GLP-1 RA class as a whole, and provides recommendations on safe use.

Save, Share, Print Article

Share this article

+ Add to reading list – Remove from reading list

↓ Download pdf

Readers are directed to the PDF version of this article.

At a glance factsheet, Microvascular complications, Newer therapies, Retinopathy

Diabetes &
Primary Care

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Poster abstract book: 20th National Conference of the Primary Care Diabetes Society

How to: Rescue therapy in the management of type 2 diabetes

Case report: Non-overweight/non-obese type 2 diabetes

PCDS Committee election candidate biographies (2024)

Diabetes Distilled: Ethnic disparities in quality of diabetes care in Scotland

Interactive case study: Antiplatelet treatment in diabetes

Diabetes Distilled: A STEP in the right direction for people with prediabetes